HPeV3 Diversity, Recombination and Clinical Impact Across 7-years: an Australian Story.
Seweryn BialasiewiczMeryta MaySarah TozerRebecca DayAnne BernardJulian ZauggKyana GartrellSoren AlexandersenAnthony ChamingsClaire Yt WangJulia ClarkKeith GrimwoodClaire HeneyLuregn SchlapbachRobert S WareDavid SpeersRoss M AndrewsStephen LambertPublished in: The Journal of infectious diseases (2022)
The HPeV3-AR was the dominant strain during the study period. Increased hospital admissions may have been from a temporary fitness advantage and/or increased virulence.